Patents by Inventor Roy E. Wuthier

Roy E. Wuthier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9132280
    Abstract: A method of photodynamic therapy to treat diseased cells in an animal is generally provided. According to the method, 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is administered to the animal such that the 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof accumulates in the diseased cells. Then, the diseased cells containing 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is exposed to light energy (e.g., ultraviolet light).
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 15, 2015
    Assignee: University of South Carolina
    Inventors: Brian Furmanski, Roy E. Wuthier, John W. Fuseler, Jr.
  • Patent number: 8344020
    Abstract: A method of photodynamic therapy to treat diseased cells in an animal is generally provided. According to the method, 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is administered to the animal such that the 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof accumulates in the diseased cells. Then, the diseased cells containing 5-amino-2,2-dimethyl-6-[3?-(R,S)amino-4?-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is exposed to light energy (e.g., ultraviolet light).
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: January 1, 2013
    Assignee: University of South Carolina
    Inventors: Brian Furmanski, Roy E. Wuthier, John W. Fuseler
  • Patent number: 7527687
    Abstract: A cement powder is disclosed that contains reactive tricalcium phosphate nanoparticles and other ingredients required to form a cementous material. Methods of making the reactive tricalcium phosphate nanoparticles, the cement powder, the cement paste, and cured cement are also provided, as are methods and articles for using the cement.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: May 5, 2009
    Assignee: University of South Carolina
    Inventors: Brian R. Genge, Licia Wu, Glenn R. Sauer, Roy E. Wuthier, Ronald Genge
  • Patent number: 7081161
    Abstract: A cement powder is disclosed that contains reactive tricalcium phosphate nanoparticles and other ingredients required to form a cementous material. Methods of making the reactive tricalcium phosphate nanoparticles, the cement powder, the cement paste, and cured cement are also provided, as are methods and articles for using the cement.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: July 25, 2006
    Assignee: University of South Carolina
    Inventors: Brian R. Genge, Licia Wu, Glenn R. Sauer, Roy E. Wuthier, Ronald Genge
  • Patent number: 7078433
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: July 18, 2006
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • Patent number: 6808561
    Abstract: A cement powder is disclosed that contains reactive tricalcium phosphate nanoparticles and other ingredients required to form a cementous material. Methods of making the reactive tricalcium phosphate nanoparticles, the cement powder, the cement paste, and cured cement are also provided, as are methods and articles for using the cement.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: October 26, 2004
    Assignee: University of South Carolina
    Inventors: Brian R. Genge, Licia Wu, Glenn R. Sauer, Roy E. Wuthier, Ronald Genge
  • Publication number: 20040092580
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 13, 2004
    Applicant: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • Patent number: 6660765
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: December 9, 2003
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • Publication number: 20030083370
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: August 2, 2002
    Publication date: May 1, 2003
    Inventors: Roy E. Wuthier, Daotai Nie
  • Publication number: 20020073894
    Abstract: A cement powder is disclosed that contains reactive tricalcium phosphate nanoparticles and other ingredients required to form a cementous material. Methods of making the reactive tricalcium phosphate nanoparticles, the cement powder, the cement paste, and cured cement are also provided, as are methods and articles for using the cement.
    Type: Application
    Filed: October 16, 2001
    Publication date: June 20, 2002
    Applicant: University of South Carolina Research Foundation
    Inventors: Brian R. Genge, Licia Wu, Glenn R. Sauer, Roy E. Wuthier, Ronald Genge
  • Publication number: 20010011100
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Application
    Filed: March 29, 2001
    Publication date: August 2, 2001
    Inventors: Roy E. Wuthier, Daotai Nie
  • Patent number: 6225340
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: May 1, 2001
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie
  • Patent number: 5932611
    Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: August 3, 1999
    Assignee: University of South Carolina
    Inventors: Roy E. Wuthier, Daotai Nie